Auspex Pharmaceuticals Inc

Most Recent

  • uploads///Specialty
    Earnings Report

    Why Teva’s Specialty Medicines Performance Declined in 1Q15

    Teva’s new drug application for ProAir RespiClick was approved, with an expected launch of 2Q15. ProAir is the first breath-actuated dry-powder inhaler used to treat acute asthma symptoms.

    By Nicole Sario
  • uploads///ASPX acquisition
    Earnings Report

    Teva Earnings Preview: Auspex Acquisition to Support Growth

    Acquisition rationale On March 30, 2015, Teva Pharmaceutical Industries (TEVA) announced its agreement to acquire Auspex Pharmaceuticals (ASPX) for $3.2 billion in enterprise value, a 42.4% premium to the company’s closing share price of $70.91 on March 27, 2015. This step will support the company’s near- and mid-term growth. Teva share price moved up a marginal […]

    By Nicole Sario
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.